Previous 10 | Next 10 |
Vir Biotechnology and GlaxoSmithKline expect to develop 2 million doses of Covid-19 antiviral Sotrovimab in the 1st half of 2022, with more to follow in the 2nd half of 2022. An Emergency Use Authorization of Sotrovimab has been filed as an intramuscular injection for patients with mi...
Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. In this Motley Fool Live video, recorded on Jan. 26 , Fool contributors Keith Speights and Brian Orelli address a viewer's question about the stock. ...
MDJM (NASDAQ:MDJH) +64%. The OLB Group OLB +25% reports $1.35B in transaction value post CBD Merchants acquisition. Advanced Micro Devices AMD +13% on Q4 results. Xilinx (NASDAQ:XLNX) +12%. Capri Holdings CPRI +12% on Q3 results. IceCure Medical (NASDAQ:ICCM) +11%. Arrival...
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation ora...
WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for peopl...
ROIV has moved up 88% in December in reaction to a patent dispute between Moderna and Arbutus falling in favor of Arbutus. The patent is licensed to a private company called Genevant. ROIV owns an effective 88% stake through direct ownership and its stake in ABUS. ROIV's move upwa...
Roivant Sciences (ROIV +16.2%) has gained for the fifth straight session on above average volume extending its December rally to nearly 90%. Its share volatility led to a brief trading halt in morning hours. Over 2.3M Roivant (NASDAQ:ROIV) shares have changed hands so far compared to 65-day a...
BeiGene began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong and Shanghai. Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Ar...
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus (HBV). In December 2021, ABUS reported its victory in the patent dispute over Moderna, involving its licensed four-lipid nanoparticles delivery system....
Penny Stocks With High Hopes From Analysts If you’re looking for penny stocks to buy, there are plenty of things to research. You could hunt for low float stocks, companies with news, insider trading activity, or, like we’ll look at today, penny stocks with bullish analyst...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...